ReviewAmerican journal of translational research2021
Paving the way for small-molecule drug discovery.
Review in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Mol-CADiff: text-conditional molecule generation via causality-aware autoregressive diffusion.Nature communications · 2026Article
- Modulating IL-1β-induced pro-atherogenic endothelial responses through drug repurposing.Inflammopharmacology · 2026Article
- Early-Enrichment Hit Discovery via Reversible-Work c(t) Estimation in Metadynamics (CTMD).bioRxiv : the preprint server for biology · 2026Article
- Review
- CN7:1h Alleviates Inflammation, Apoptosis and Extracellular Matrix Degradation in Osteoarthritis by Modulating the NF-κB and mTOR Pathways.Journal of cellular and molecular medicine · 2025Article
- Effects of naphthoquinone scaffold-derived compounds on head and neck squamous cell carcinoma based on network pharmacology and molecular docking.International journal of clinical and experimental pathology · 2025Article
- Substituted 1,4-naphthoquinones for potential anticancer therapeutics:Computational and structural biotechnology journal · 2025Article
- Investigating impacts of the mycothiazole chemotype as a chemical probe for the study of mitochondrial function and aging.GeroScience · 2024Article
- Recent Advances in the Discovery of Novel Drugs on Natural Molecules.Biomedicines · 2024Article
- Investigating the immune mechanism of natural products in the treatment of lung cancer.Frontiers in pharmacology · 2024Review
- Drug Design for Alzheimer's Disease: BiologicsCurrent Alzheimer research · 2024Review
- DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors.Communications chemistry · 2023Article
- Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Molecules (Basel, Switzerland) · 2023Article
- The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins, which have a low molecular weight, making them penetrate cells easily. Small-molecule drugs can be developed from leads derived from rational drug design or isolated from natural resources. As commonly used medications, small-molecule drugs can be taken orally, which enter cells to act on intracellular targets. These characteristics make small-molecule drugs promising candidates for drug development, and they are increasingly favored in the pharmaceutical market. Despite the advancements in molecular genetics and effective new processes in drug development, the drugs currently used in clinical practice are inadequate due to their poor efficacy or severe side effects. Therefore, developing new safe and efficient drugs is a top priority for disease control and curing.
Indexed as
Identifiers
33841626PMC8014367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.